InnovHeart has completed the first U.S. implantation of its investigational Saturn Transseptal Transcatheter Mitral Valve Replacement system, expanding the CASSINI clinical program into the United States. The procedure was performed at NewYork-Presbyterian/Columbia University Irving Medical Center in an 86-year-old woman with severe symptomatic functional mitral regurgitation. InnovHeart said the valve was delivered percutaneously across the atrial septum, produced an excellent hemodynamic result and eliminated mitral regurgitation in the patient.
The U.S. case brings the total number of Saturn-treated patients across the CASSINI program to 15, including earlier European experience. InnovHeart reports that patients followed in Europe for as long as two years have experienced no procedural mortality, no left ventricular outflow tract obstruction and reduction of mitral regurgitation to mild or less in every implanted patient. These early observations are encouraging but come from a very small clinical population, and Saturn remains investigational and unavailable commercially in any country.
Why is transcatheter mitral valve replacement more difficult than replacing an aortic valve?
The mitral valve has a large, irregular and highly variable anatomy, and its position places a replacement device close to the left ventricular outflow tract through which blood must leave the heart. A valve or surrounding tissue that protrudes into that pathway can obstruct blood flow, creating one of the most feared complications of transcatheter mitral valve replacement.
Mitral regurgitation also occurs through several disease mechanisms rather than one uniform anatomical defect. A successful TMVR system therefore needs to anchor reliably across different anatomies, prevent leakage, avoid obstructing the ventricle and remain stable under substantial mechanical forces. InnovHeart designed Saturn specifically around these challenges and identifies anatomical variability and LVOT obstruction as central development priorities.
What happened during the first U.S. Saturn procedure?
The August 25 procedure involved a patient with functional symptomatic severe, grade 4+ mitral regurgitation. Physicians advanced Saturn through a percutaneous transseptal route rather than using open-heart surgery, implanted it in the native mitral position and reported elimination of the regurgitation with favorable immediate hemodynamics.
One successful case cannot establish overall safety or effectiveness, which is why the procedure is being conducted under the CASSINI-US Early Feasibility Study. The value of an early feasibility program is that investigators can assess device delivery, positioning and immediate physiological performance before exposing a much larger population to a new structural heart system.
What do the first 15 patients tell us about Saturn?
InnovHeart’s reported experience contains several encouraging early signals. Across the small global clinical cohort, the company says no procedural deaths or LVOT obstruction have occurred, and mitral regurgitation has been reduced to mild or less in all implanted patients, with stable hemodynamic performance in early European participants followed for as long as two years.
The small denominator needs to remain prominent. Rare but catastrophic complications may not appear in the first 15 patients, and early procedures are generally conducted by highly experienced operators at specialist centers. The development program must therefore reproduce these outcomes across a much larger and more varied patient population before Saturn can compete as a routine TMVR platform.
Why could TMVR become a major medtech category?
Transcatheter mitral repair already provides an alternative for selected patients who cannot undergo conventional surgery, but replacement could potentially treat anatomies that are difficult to address reliably with repair alone. The opportunity is especially relevant among older and high-risk patients whose surgical risk makes open valve replacement unattractive.
The technical barriers explain why TMVR has progressed more slowly than transcatheter aortic valve replacement. InnovHeart’s U.S. milestone therefore matters not because 15 patients constitute definitive evidence, but because another platform has successfully crossed from European early experience into FDA-regulated U.S. feasibility testing.